Merus

328 posts

Merus banner
Merus

Merus

@MerusNV

Clinical-stage oncology company developing Biclonics® bispecific antibody therapeutics. Please see our Community Guidelines: https://t.co/qN9crK04bE

Katılım Ekim 2019
166 Takip Edilen312 Takipçiler
Sabitlenmiş Tweet
Merus
Merus@MerusNV·
Based on the opinions of our employees, we’re a 2022 World Class Workplace. This label is awarded by Effectory to celebrate organizations who are dedicated to their people. Thanks to everyone at Merus who makes our organization a great place to work. #CloseInOnCancer
Merus tweet media
English
0
1
12
0
Merus
Merus@MerusNV·
We look forward to sharing robust updated interim phase 2 data on petosemtamab plus pembrolizumab as first line treatment for PD-L1+ r/m #HNSCC, on the entire 45 patient data set, on an upcoming investor conference call on May 22 at 5:30 p.m. ET and in our presentation at #ASCO25. We continue to believe petosemtamab has the potential to be a first and best in class, practice-changing medicine for the treatment of r/m #HNSCC. #CloseInOnCancer ir.merus.nl/news-releases/…
Merus tweet media
English
0
1
4
345
Merus
Merus@MerusNV·
In May 2024 and February 2025, the U.S. FDA granted Breakthrough Therapy designations to petosemtamab: as monotherapy in 2L+ r/m #HNSCC, and in combination with pembrolizumab in 1L PD-L1+ r/m #HNSCC, respectively. We are dedicated to advancing petosemtamab as a potential new therapy for the treatment of r/m #HNSCC. #ClosingInOnCancer
Merus tweet media
English
0
1
2
292
Merus
Merus@MerusNV·
Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN2 trial has over 93 sites open across North and South America, Europe, Asia, and Australia. For more information, visit clinicaltrials.gov/study/ NCT06496178. #CloseInOnCancer
Merus tweet media
English
0
2
4
272
Merus
Merus@MerusNV·
Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN1 trial has over 105 sites open across North and South America, Europe, Asia, and Australia. For more information, visit clinicaltrials.gov/study/ NCT06525220. #CloseInOnCancer
Merus tweet media
English
0
2
6
313
Merus
Merus@MerusNV·
At Merus, every day, we bring a sense of urgency and a passion to help patients. In April we recognize the patients with recurrent/metastatic #HNSCC. We remain steadfast in our commitment to advance our lead cancer drug candidate petosemtamab as a potential new treatment for patients. #CloseInOnCancer
Merus tweet media
English
0
2
5
220
Merus
Merus@MerusNV·
Bill Lundberg, MD, Merus’ CEO, will present today at Citi’s 2025 Virtual Oncology Leadership Summit. The presentation will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer
Merus tweet media
English
1
1
6
219
Merus
Merus@MerusNV·
Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat today at the Stifel 2024 Healthcare Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer
Merus tweet media
English
0
0
2
211
Merus
Merus@MerusNV·
Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer
Merus tweet media
English
0
0
3
142
Merus
Merus@MerusNV·
The Merus team recently celebrated the end of summer and welcomed the start of the fall season with a fun and highly competitive outing. #Team #CloseInOnCancer
Merus tweet media
English
0
1
4
154
Merus
Merus@MerusNV·
Please join us in welcoming Audrey as our Chief People Officer. Audrey has more than 25 years of experience attracting, developing, and retaining top talent in the pharmaceutical and biotechnology industries. We're excited to have her on the team as we #CloseInOnCancer.
Merus tweet media
English
0
1
3
553
Merus
Merus@MerusNV·
We are excited for Adair to join the Merus team as our Internal Communications Officer. Welcome aboard! #CloseInOnCancer
Merus tweet media
English
0
0
2
176
Merus
Merus@MerusNV·
We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab 1L r/m #HNSCC #CloseInOnCancer
Merus tweet media
English
0
1
6
219
Merus
Merus@MerusNV·
We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab in 1L PD-L1+ r/m  #HNSCC #CloseInOnCancer ir.merus.nl/news-releases/…
Merus tweet media
English
0
1
7
212